The global analgesics market size was valued at USD 38.60 billion in 2022 and is projected to reach USD 61.39 billion by 2030, growing at a CAGR of 6.02% from 2023 to 2030. The rise in incidences of arthritis and osteoarthritis, neuropathic diseases, and cancer is expected to drive market growth during the forecast period.

 

Additionally, the growing efforts of pharmaceutical companies to develop novel analgesics to manage pain and related disorders are anticipated to provide lucrative growth opportunities. For instance, as of October 2022, there were 17 novel pain relief drugs in development phases in the U.S., of which 16 were in phase 3 clinical trials. In May 2020, Assertio Holdings, Inc. merged with Zyla Life Sciences to enhance its pain management product portfolio.

 

The increasing prevalence of targeted diseases is expected to further propel market growth over the forecast period. According to the CDC, approximately 1 in 4 U.S. adults (23.7%), or about 58.5 million people, are diagnosed with arthritis. This condition is more prevalent in women compared to men, and its incidence increases with age.

 

Osteoarthritis is a leading form of arthritis, while fibromyalgia and gout are among the common rheumatic conditions. Common analgesics used in managing arthritis include celecoxib, naproxen, ibuprofen, diclofenac, and etodolac, among others. Therefore, the surge in the prevalence of arthritis serves as a major driving factor in the analgesics market.

 

Key Market Trends & Insights

  • In 2022, North America led the global analgesics market with a revenue share of 31.76%. This dominance is attributed to the presence of several leading players engaging in various strategic initiatives, along with significant investments in analgesics-focused R&D in the region.
  • By drug type, the non-opioid segment dominated the analgesics market, holding a share of 52.01% in 2022. This is due to the increasing demand for non-opioid analgesics, which have a lower risk of adverse effects, strong availability of generic preparations, and various initiatives by private organizations and governments promoting non-opioid options for pain management.
  • By route of administration, the oral segment led the analgesics market with a share of 47.88% in 2022. Factors such as the convenient administration of analgesics via the oral route and its non-invasive nature significantly contribute to this segment’s market share.
  • By application, the surgical and trauma segment held the largest share of 22.71% in the analgesics market in 2022. This high market share is due to the increasing demand for painkillers during and after surgeries, rising incidences of traumatic injuries, and various initiatives aimed at managing traumatic events.
  • By distribution channel, the retail pharmacies segment dominated the analgesics market with a revenue share of 50.96% in 2022. The growth of this segment is attributed to the rising availability of OTC prescriptions, high penetration of generics, and the increasing number of analgesics prescriptions due to the growing incidence rate of pain and injuries.

 

Order a free sample PDF of the Analgesics Market Intelligence Study, published by Grand View Research.

 

Market Size & Forecast

  • 2022 Market Size: USD 38.60 billion
  • 2030 Projected Market Size: USD 61.39 billion
  • CAGR (2023-2030): 6.02%
  • North America: Largest market in 2022
  • Asia Pacific: Fastest growing market in 2022

 

Key Companies & Market Share Insights

Key market players are implementing strategies such as new product development, mergers and acquisitions, and partnerships to expand their market share. For instance, in March 2023, Pfizer Inc. received U.S. FDA approval for its ZAVZPRET, the first CGRP receptor antagonist nasal spray for treating acute migraine in adults. Such initiatives are expected to propel market growth during the forecast period.

Key Players

  • Bayer AG
  • Endo International plc
  • Assertio Holdings, Inc.
  • Janssen Global Services, LLC
  • GSK plc
  • AbbVie Inc.
  • Novartis AG
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.

 

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

 

Conclusion

The analgesics market is set for substantial growth, driven by the increasing prevalence of pain-related conditions and the ongoing development of innovative pain management solutions. The focus on non-opioid analgesics, along with strategic initiatives by key players, positions the market for continued expansion. As consumer demand rises and new treatments emerge, the analgesics market will likely evolve to meet the diverse needs of patients and healthcare providers.